SBI Japan-Israel Innovation Fund

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 9
Average round size
info
The average size of a deal this fund participated in
$24M
Portfolio companies 7
Rounds per year 2.25
Lead investments 0
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.22
Exits 3
Key employees 3
Stages of investment
Early Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Medical
Summary

The venture was found in Asia in Israel. The main department of described VC is located in the Herzliya.

The fund has no exact preference in a number of founders of portfolio startups. In case when startup counts 3 or 5+ of the founder, the chance for it to get the investment is meager. Among the most popular fund investment industries, there are Biotechnology, Clinical Trials. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline BIOMx, Orasis Pharmaceuticals, ChemomAb For fund there is a match between the country of its foundation and the country of its the most frequent investments - Israel.

Besides them, we counted 3 critical employees of this fund in our database.

The important activity for fund was in 2019. The fund is constantly included in 2-6 deals per year. The top amount of exits for fund were in 2018. Comparing to the other companies, this SBI Japan-Israel Innovation Fund performs on 15 percentage points less the average number of lead investments. Deals in the range of 10 - 50 millions dollars are the general things for fund.

The typical case for the fund is to invest in rounds with 5-6 participants. Despite the SBI Japan-Israel Innovation Fund, startups are often financed by OrbiMed, Takeda Ventures, Seventure Partners. The meaningful sponsors for the fund in investment in the same round are OrbiMed, Takeda Ventures, Seventure Partners. In the next rounds fund is usually obtained by Takeda Ventures, Seventure Partners, RM Global Partners.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of SBI Japan-Israel Innovation Fund:
Typical Co-investors
SBI Japan-Israel Innovation Fund is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after SBI Japan-Israel Innovation Fund:

Funds with similar focus

Funds from Israel
Funds with similar focus located in Israel:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Broad Resources China, Shanghai
Chesapeake Solar Jessup, Maryland, United States
Circle T Partners New York, New York, United States
DCB BANK India, Maharashtra, Mumbai
Enzo Ventures -
Extend Capital -
FGL Holdings Cayman Islands, Grand Cayman
G7 Renewable Energies Gauteng, NA - South Africa, South Africa
Hongdao Dianying Jinrong China, Hangzhou, Zhejiang
Huagen Touzi China, Guangdong, Guangzhou
IMG Investment Partners -
LTS Investments Brazil, São Paulo, Sao Paulo
Maverick Capital Dallas, Texas, United States
Nanjing Guanghe Hudong Touzi China, Jiangsu, Nanjing
Naturals Chennai, India, Tamil Nadu
NTT Data Japan, Koto
Shanghai Wenyuan Touzi Guanli Zhongxin (Youxian Hehuo) China, Shanghai
Shiga Bank Japan, Otsu, Shiga Prefecture
Shin Kong Life Insurance -
Tackle Capital -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Orasis Pharmaceuticals

Clinical Trials
Health Care
Medical
Pharmaceutical
$30M10 Sep 2020 Israel, Tel Aviv District, Israel

BioSight

Biotechnology
Health Care
Pharmaceutical
Therapeutics
$19M11 Mar 2020 Israel, North District

Ayala Pharmaceuticals

Biotechnology
Pharmaceutical
$30M28 May 2019 Israel, Center District

BIOMx

Biotechnology
Health Care
Therapeutics
$32M20 Feb 2019 Israel, North District, Israel

Biond Biologics

Biotechnology
Health Care
Pharmaceutical
$17M08 Jan 2019 Israel, North District

Orasis Pharmaceuticals

Clinical Trials
Health Care
Medical
Pharmaceutical
$13M05 Jun 2018 Israel, Tel Aviv District, Israel

ChemomAb

Biotechnology
Health Care
Pharmaceutical
$10M04 Dec 2017 Tel Aviv-Yafo, Tel Aviv District, Israel

LogicBio Therapeutics

Biotechnology
Genetics
$45M29 Jun 2017 California, United States

BIOMx

Biotechnology
Health Care
Therapeutics
$24M15 May 2017 Israel, North District, Israel

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent SBI Japan-Israel Innovation Fund?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: